Ownership and insider activity for BioAge Labs Inc. (BIOA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Price
| Price | $7.75 |
| Market Cap | $292M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-29 | Barton Shane | M-Exempt | 14,198 | $62K |
| 2026-06-30 | Barton Shane | M-Exempt | 7,861 | $34K |
| 2026-06-29 | Barton Shane | M-Exempt | 14,198 | $62K |
| 2026-06-29 | Barton Shane | M-Exempt | 8,958 | $39K |
| 2026-06-29 | Barton Shane | M-Exempt | 8,958 | $39K |
| 2026-06-30 | Barton Shane | M-Exempt | 4,065 | $17K |
| 2026-06-29 | Barton Shane | M-Exempt | 7,261 | $61K |
| 2026-06-30 | Barton Shane | M-Exempt | 7,861 | $34K |
| 2026-06-29 | Barton Shane | M-Exempt | 7,261 | $61K |
| 2026-06-29 | Barton Shane | M-Exempt | 9,301 | $101K |
Balance Sheet (10y)
| Year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $27.6M | $21.6M | $354.3M | $188.9M |
| Short-term Investments | 0 | 0 | 0 | $92.2M |
| Receivables | 0 | 0 | 0 | $769000 |
| Inventory | 0 | 0 | 0 | 0 |
| Total Current Assets | $28.0M | $25.3M | $357.1M | $286.8M |
| Property, Plant & Equipment | $374000 | $518000 | $791000 | $3.7M |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Total Assets | $28.4M | $25.9M | $358.2M | $294.9M |
| Accounts Payable | $2.3M | $1.9M | $2.0M | $2.7M |
| Short-term Debt | $167000 | $44.9M | $6.0M | $2.6M |
| Total Current Liabilities | $5.9M | $58.2M | $27.8M | $20.1M |
| Long-term Debt | $2.3M | $8.2M | $2.5M | $2.3M |
| Total Liabilities | $141.0M | $199.3M | $35.1M | $22.8M |
| Retained Earnings | -$117.8M | -$181.7M | -$252.8M | -$333.4M |
| Total Equity | -$112.6M | -$173.4M | $323.1M | $272.1M |
| Total Debt | $2.5M | $53.3M | $8.7M | $5.6M |
| Net Debt | -$25.2M | $31.6M | -$345.6M | -$275.5M |
| Working Capital | $22.2M | -$32.9M | $329.3M | $266.7M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 17.19 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 10.98 |
Profitability
| Return on Equity | -28.99% |
| Return on Invested Capital | -28.08% |
| Return on Assets | -23.80% |
| Gross Margin | 99.39% |
| Operating Margin | -1026.28% |
| Net Margin | -912.25% |
Related companies: ACB · ALLO · AVIR · CABA · CGC · EDIT · HUMA
Explore sector: Healthcare · Biotechnology
More sections of BIOA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks